Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer

Prostate Cancer Clinical Trial

— ESCAPE-ING  

Official title:

Effect of Sulforaphane on Prostate CAncer PrEvention-imagING Evaluation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02404428
• Other study ID #: IFR02/2014
• Status: Terminated
• Phase: N/A
• First received: March 23, 2015
• Last updated: November 23, 2016
• Start date: February 2015
• Est. completion date: September 2016

Study information

• Verified date: November 2016
• Source: Institute of Food Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Prostate cancer is a major public health problem and there is a strong need of new preventive strategies based on drug and lifestyle interventions. It is now well-established that healthy eating patterns and increasing physical activity can prevent or delay prostate cancer progression. Intake of cruciferous vegetables (e.g. broccoli, cabbage, cauliflower, Brussels sprouts, kale) has been associated with decreased risk of prostate cancer progression; however the underlying biological mechanisms remain unknown. The investigators propose to undertake a pilot study on a group of men with early prostate cancer on active surveillance to determine whether a diet rich in broccoli will induce changes in tumor size and blood flow measured by conventional Magnetic Resonance Imaging (MRI) techniques. Men with early prostate cancer on active surveillance who have visible cancer lesions on MRI will be recruited onto this double-blinded randomized intervention and they will be asked to eat one portion of broccoli soup per week for 6 months. The investigators will test two varieties of broccoli (standard and 'Beneforte extra' broccoli) that are able to deliver two different levels of sulforaphane (SF), an active compound extensively studied for its potential anticancer properties. This study will involve MRI scans, blood and urine collection before and after a 6 month intervention period. This study design will not only allow us to observe diet-induced changes within the prostate but also at the systemic level. In addition, participant's lifestyle (habitual diet and physical activity) will be assessed by food diaries and exercise questionnaires.

This study has been funded by Biotechnology and Biological Sciences Research Council (BBSRC) and Prostate Cancer foundation (PCF).

Description:

The study is a randomised double-blinded dietary intervention study. The study population will consist of men (n=20) aged 18-80 years with a BMI between 19.5 and 35 kg/m2 with low risk prostate cancer (prostate specific antigen [PSA] < 10ng/ml; Gleason grade 6; T category T1 or T2) or intermediate risk prostate cancer patients (PSA 10-20ng/ml; Gleason 7 (including selected 4+3 cases that will not be advised for radical prostatectomy; T category T1 or T2) who have visible lesions on MRI and have already decided to take up active surveillance/monitoring. The investigators chose these inclusion criteria because they reflect the population of men on active surveillance that the investigators are currently recruiting in the ESCAPE study (Effect of Sulforaphane on Prostate CAncer PrEvention; ClinicalTrials.gov Identifier: NCT01950143) via the Norfolk and Norwich University Hospital. Volunteers recruited onto this study will be randomly allocated to one of two arms in which they will be required to consume one portion of broccoli soup per week, delivering different levels of glucoraphanin (SF precursor) in each study arm. This will be part of their normal diet for 6 months. The two soups will contain standard broccoli (i), or glucoraphanin-enriched broccoli named for the study 'Beneforte extra' (ii). The study will involve MRI monitoring at baseline and after 6 months. In addition the investigators will collect blood and urine samples at baseline and after 6 months. The volunteers' habitual diet and physical activity will also be assessed during the intervention period.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Suitable for and have chosen AS as management for localised prostate cancer

• MRI visible detected lesion =0.5 cm in the axial plane, corresponding to the biopsy confirmed region of prostate cancer

• No contraindication to MR scanning

• Aged 18-80 years

• BMI between 19.5 and 35 kg/m2

• Smokers and non-smokers

Exclusion Criteria:

• 5a-reductase inhibitors or testosterone replacement medicines

• warfarin

• surgically implanted pelvic metalwork

• pacemakers or other implanted electronic devices not compatible with MRI

• contra-indications to gadolinium-based contrast agents (including patients with abnormal renal function)

• Glomerular Filtration Rate (GFR) <60 ml/min

• claustrophobia

• allergies to any of the ingredients of the broccoli soups

• dietary supplements or herbal remedies which may affect the study outcome - unless the volunteer is willing to discontinue taking them for 1 month prior to starting study

• parallel participation in another research project that involves dietary intervention

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Dietary Supplement:
• Standard broccoli soup
300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
• Beneforte extra broccoli soup
300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)

Locations

Country	Name	City	State
United Kingdom	Cambridge University Hospitals NHS Foundation Trust_Addenbrooke's Hospital	Cambridge

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Food Research	Cambridge University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	tumor size/blood flow	change in prostate tumor/blood flow size determined by MRI methods within the prostate gland	6 months	No
Secondary	choline + creatine/citrate ratio	concentration of metabolites (choline + creatine/citrate ratio) in the prostate tissue determined by using MR spectroscopy	6 months	No
Secondary	citrate levels	concentration of citrate and associated metabolites in body fluids (blood, urine)	6 months	No
Secondary	PSA levels	plasma levels of prostate-specific antigen (PSA) and other blood markers	6 months	No
Secondary	GSTM1 genotype	Glutathione S-transferase Mu 1 (GSTM1) genotype or other relevant genotypes on mediating metabolite changes by diet	6 months	No